Clinical trial
Amendment (g) Unblinded Extension Phase of Somatropin in Patients With…
NCT00191074 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00191074 |
|---|---|
| Title | Amendment (g) Unblinded Extension Phase of Somatropin in Patients With Idiopathic Short Stature |
| Official title | Phase III Study of Humatrope in Non-Growth Hormone Deficient Children With Short Stature |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Growth Disorder |
| Intervention type | Drug |
| Interventions | somatropin, rDNA origin, for injection |
| Enrollment | 11 |
| Start date | Feb 1, 2001 |
| Completion | Jan 1, 2006 |
| First posted | Sep 19, 2005 |
| Last update posted | Mar 9, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: